Abstract:With great interest, we read the recent article published by Songur et al. 1. In this article, the authors have compared the effect of epidermal growth factor (EGF) injection on skin hydrofluoric acid (HF) burns with those of magnesium sulphate and calcium gluconate injections, indicating that EGF limited HF damage morphologically and histologically, more effectively than Ca2+ or Mg2+. These results are encouraging and of major interest. Although subcutaneous injection of EGF certainly has the potential to be a better method for skin HF treatments, we have some concerns about the interpretation of the results. As known, HF is a hazardous inorganic acid, which causes not only corrosive effects on topical tissues but also systemic toxicity 2, 3. The severity of HF burns is closely associated with the concentration of HF, the duration of contact and the characteristics of the topical tissues involved 4, 5. The critical procedure to treat HF burn is to prevent on-going HF absorption and block the progressive destruction caused by fluoride ions 6. The common neutralising agents include calcium gluconate, magnesium sulphate and some other chelating agents. To date, topical application of calcium gluconate gel is a recommended therapy in the first aid of HF burns 7, 8. Due to poor tissue penetrability of calcium and magnesium ions, topical application can neutralise fluoride ions only on or in the superficial layers of the skin. Subcutaneous injection of calcium/magnesium agents, partially overcoming the limitations of external application, is suitable for skin sites with soft tissue and for patients with extensive HF burns or those insensitive to topical application. The dose of chelating agents delivered by subcutaneous injection can be very critical for the effective treatment of skin HF burns. In clinical practice, 10% calcium gluconate is recommended for use as injection treatment at 0·5 ml/cm2 9, 10. However, the accurate dose of calcium gluconate used in this article is not provided for some reason. It is the responsibility of the authors to provide detailed information and further clarify what criteria have been used to determine the injection dose of calcium, magnesium agents and EGF. In this study, the authors took the changes in rat body weight to evaluate fluid loss. It is worth noting whether this method is suitable. The authors have specified the method used to measure the body weights of rats but have not given any information regarding the feeding of the experimental animals post-burn. It is known that intensive pain can be caused by HF burns. Pain has the potential to affect the rats' emotions, feeding habits and changes in body weights. As the treatment modalities mentioned in this article could produce different levels of pain relief, it will be objective to further assess the fluid loss by measuring the amount of intake and output of the rats. Finally, compared with the inorganic ions, EGF as a bioactive factor must play a more positive role in the tissue responses unless deactivated. In this article, the readers could refer to the explanations on the chelating role and mechanism of EGF in HF burns, rather than its role in wound healing. However, a chelating agent such as EGF is welcome because of its positive role in the prevention of HF damage and in wound healing. Yunanhai Zhang & Liangfang Ni Department of Burns and Plastic Surgery Quhua Hospital of Zhejiang Quzhou, China Xingang Wang & Chunmao Han Department of Burns & Wound Care Center 2nd Affiliated Hospital of Zhejiang University, College of Medicine Hangzhou, China wxg8157@gmail.com

[The Effects of Epidermal Growth Factor on the Wound Healing of Deep Partial Thickness Burn in Rats].

[A Study on the Promoting Effects of Recombinant Human Epidermal Growth Factor on Skin Wound Healing in Rats].

[Effect of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor on Wound Healing in Patients with Deep Partial Thickness Burn].

Healing properties of epidermal growth factor and tocotrienol-rich fraction formulation in deep partial-thickness burn wound model

Effect of Growth Hormone on IGF-I/EGFBP Mrna in Healing of Thermal Wound

Subcutaneous Injection of Epidermal Growth Factor for Skin Hydrofluoric Acid Burns

Topical application of epidermal growth factor accelerates wound healing by myofibroblast proliferation and collagen synthesis in rat

Effect of recombinant human keratinocyte growth factor-2 on burn wound healing in rats and its probable mechanisms of action

Hydrogel With Recombinent Human Erythropietin Improves Angiogenesis and Wound Healing in Experimental Rat Burn Wounds

[Purification of Recombinant Fusion Polypeptide Hegf-Awrk6 and Effect on Wound Healing and Infection of Burn Model Mice].

Effect of recombinant human granulocyte-macrophage colony stimulating factor gel on melting crust in deep partial thickness scalding rats

Evaluation of a highly skin permeable low-molecular-weight protamine conjugated epidermal growth factor for novel burn wound healing therapy

[Effect of Exogenous Basic Fibroblast Growth Factor on Proliferation and Migration of Endothelial Cells of Partial Thickness Scald in Rats].

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on wound debridement and healing of deep II thickness burn]

Prosthetic effect of recombinant human epidermal growth factor combined with basic fibroblast growth factor on diabetic wound healing

Acceleration of deep Ⅱ° burn healing by using recombinant human granulocyte-macrophage colony stimulating factor gel

Recombinant Human Platelet-Derived Growth Factor Enhances Repair of Cutaneous Full-Thickness Excision by Increasing the Phosphorylation of Extracellular Signal-Regulated Kinase in Diabetic Rat.

Experimental Study of Epidermal Growth Factor and Acidic Fibroblast Growth Factor in the Treatment of Diabetic Foot Wounds.

Effects of Rhgm-Csf on Scalding Wound Healing and Neovascularization in Rats

[The Effect of Growth Hormone on Wound Healing Rate in Adult Burns].

Recombinant Human Platelet-Derived Growth Factor Enhanced Dermal Wound Healing by a Pathway Involving ERK and C-Fos in Diabetic Rats.